New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Rod Baber

Prof Rod Baber

Menopausal Hormone Therapy - What Dose of Estrogen is Best?

Dr Adam Nelson

Dr Adam Nelson

Cardiovascular Benefits of GLP1s – New Evidence

Dr Kathleen McNamee, Prof Sonia Grover

Dr Kathleen McNamee, Prof Sonia Grover

Oral Contraceptive Pill in Teens

Prof Andrew Sindone

Prof Andrew Sindone

RSV and the Heart

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 1 January 1970